NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.81 0.00 (0.00%) GOLD FUTURES
2,328.20 -10.20 (-0.44%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,589.06 -1,721.14 (-3.23%)
Photocure ASA (0IMT.L)
- PR Newswire
European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the 2024 European Association of Urology congress (EAU) in Paris, France, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
- PR Newswire
Photocure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024.
- PR Newswire
New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week. This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
